← All trials
NCT05084118
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 21, 2021
- Primary completion
- Nov 1, 2023
- Completion date
- Jun 1, 2024
- First posted
- Oct 19, 2021
- Last posted
- Oct 22, 2021
- Enrollment
- 164
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Medical University of ViennaLead sponsor
- Medical University of ViennaOverall official - principal investigator
- Medical University of ViennaReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.